Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia

被引：68
|
作者：
Ghia, Paolo [1 ,2 ]
Scarfo, Lydia [1 ,2 ]
Perez, Susan [3 ]
Pathiraja, Kumudu [3 ]
Derosier, Martha [3 ]
Small, Karen [3 ]
Sisk, Christine McCrary [3 ]
Patton, Nigel [4 ]
机构：
[1] Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy
[2] IRCCS Ist Sci San Raffaele, Milan, Italy
[3] Merck & Co Inc, Kenilworth, NJ USA
[4] Auckland City Hosp, Auckland, New Zealand
来源：
BLOOD | 2017年 / 129卷 / 13期
关键词：
DEPENDENT KINASE INHIBITOR; SCH; 727965; CANCER; FLAVOPIRIDOL; FLUDARABINE; CELLS; MALIGNANCIES; APOPTOSIS; IBRUTINIB; SCHEDULE;
D O I：
10.1182/blood-2016-10-748210
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1876 / 1878
页数：3
相关论文
共 50 条
  • [1] A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia
    Ghia, Paolo
    Scarfo, Lydia
    Pathiraja, Kumudu
    Derosier, Martha
    Small, Karen
    Patton, Nigel
    BLOOD, 2015, 126 (23)
  • [2] Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia
    Reagan, John L.
    Castillo, Jorge J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 151 - 160
  • [3] Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Tuscano, Joseph
    Poh, Christina
    Rosenberg, Aaron
    Jonas, Brian
    Abedi, Mehrdad
    Barisone, Gustavo
    Schwab, Emily
    Lundeberg, Kathleen
    Kaesberg, Paul
    JOURNAL OF HEMATOLOGY, 2020, 9 (03) : 79 - 83
  • [4] Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy
    Nikolaenko, Liana
    Liu, Tingting
    Danilov, Alexey V.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (05) : 481 - 487
  • [5] Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
    Castro, J. E.
    Choi, M. Y.
    Carvajal, T.
    Almahasnah, E.
    Chang, J.
    James, D. F.
    Kipps, T. J.
    BLOOD CANCER JOURNAL, 2014, 4 : e258 - e258
  • [6] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kevin J. Freise
    Aksana K. Jones
    Doerthe Eckert
    Sven Mensing
    Shekman L. Wong
    Rod A. Humerickhouse
    Walid M. Awni
    Ahmed Hamed Salem
    Clinical Pharmacokinetics, 2017, 56 : 515 - 523
  • [7] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Freise, Kevin J.
    Jones, Aksana K.
    Eckert, Doerthe
    Mensing, Sven
    Wong, Shekman L.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 515 - 523
  • [8] Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
    J E Castro
    M Y Choi
    T Carvajal
    E Almahasnah
    J Chang
    D F James
    T J Kipps
    Blood Cancer Journal, 2014, 4 : e258 - e258
  • [9] Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kataeva, Elena
    Golenkov, Anatoly
    Triphonova, Elena
    Dudina, Galina
    Mitina, Tatyana
    Lutskaya, Tatyana
    Vysotskaya, Ludmila
    Chernykh, Yulliya
    Zakharov, Sergey
    BLOOD, 2013, 122 (21)
  • [10] Efficacy and Safety of Ofatumumab in Patients with Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 200 - 202
12345